"Designing Growth Strategies is in our DNA"

Contract Manufacturing Organizations (CMO) Market Size, Share & Industry Analysis, By Service (API Manufacturing, Finished Product {Solid Dosage Forms, Injectables, and Others}, and Packaging), and Regional Forecast, 2024-2032

Last Updated: October 11, 2024 | Format: PDF | Report ID: FBI102658

 

KEY MARKET INSIGHTS

Play Audio Listen to Audio Version

The global Contract Manufacturing Organizations (CMO) market size was valued at USD 145.32 billion in 2023. The market is projected to grow from USD 156.29 billion in 2024 to USD 289.68 billion by 2032, exhibiting a CAGR of 8% during the forecast period.


A Contract Manufacturing Organization (CMO) is a specialized company that provides comprehensive manufacturing services to the pharmaceutical and biotechnology industries. CMOs assist companies in the pharmaceutical industry by handling the production of a drug substance, allowing them to outsource manufacturing processes that they may not have the manufacturing capacities or resources for managing in-house. This includes services, such as formulation development, stability studies, and commercial production, all the while ensuring compliance with the regulatory standards, such as the Good Manufacturing Practices (GMP) mandated by the regulatory bodies, such as the U.S. FDA.


Contract Manufacturing Organizations (CMO) play a crucial role in the pharmaceutical supply chain, enabling companies to scale operations efficiently and focus on their core activities, which include drug discovery and marketing. By partnering with the CMOs, pharmaceutical firms can reduce costs, accelerate time-to-market, and access specialized expertise, which is becoming increasingly vital in a competitive global market.


The market’s growth can be attributed to advancements in biopharmaceutical manufacturing technologies and growing focus on personalized medicine and gene therapies, which are creating new opportunities for the Contract Manufacturing Organizations (CMO). Moreover, the increasing demand for generic pharmaceuticals is prompting several healthcare companies to outsource manufacturing activities to CMOs, enhancing efficiency and reducing costs. This is anticipated to fuel the market growth in the coming years.


The global market witnessed positive growth during the COVID-19 pandemic. This growth is credited to an increase in the number of COVID-19 cases, which fueled the demand for several drugs and increased the need for large-scale manufacturing. To fulfill these needs, several pharmaceutical and biotechnology companies partnered with the Contract Manufacturing Organization (CMO), which contributed to the market growth.



  • For instance, in June 2020, Moderna, Inc. entered a partnership with Catalent, Inc. for the large-scale, commercial fill-finish manufacturing of Moderna's mRNA-based COVID-19 vaccine candidate (mRNA-1273). The production was carried out at the Bloomington biologics facility in Indiana, U.S.


After the COVID-19 pandemic, the market is set to expand at a normal growth rate due to the reduction in the demand for COVID-19-related products, changes in capacity expansion plans, and increased focus on non-COVID-19 therapeutics.


Contract Manufacturing Organizations (CMO) Market Trends


Adoption of Digitization and Automation in CMOs to Improve Production Capabilities


In terms of current market trends, the Contract Manufacturing Organizations (CMOs) are increasingly integrating digital technologies and automation to improve their production capabilities and meet the rising global demand for several drugs.



  • For instance, in May 2024, Samsung Biologics, a CMO, completed the digital connectivity phase, which allowed it to offer advanced AI-driven services to its biopharma partners. This technological adoption is boosting their efficiency, providing a competitive edge, and lowering their costs and risks.


The implementation of digitization and automation is enabling CMOs to optimize their manufacturing workflows, minimize manual errors, and improve Overall Equipment Effectiveness (OEE). This is leading to greater efficiency, higher production rates, and reduced expenses. Furthermore, these digitized, automated systems are helping CMOs maintain stringent quality standards and comply with the Good Manufacturing Practices (GMP) essential in the pharmaceutical sector. In addition, the shift toward digitalized aseptic production is offering several benefits over the conventional aseptic manufacturing processes, positively impacting the entire production process.



  • For instance, an article published by the International Society of Pharmaceutical Engineering (ISPE) in March 2023 highlighted that the digitalized aseptic production model incorporates advanced features, such as paperless production, 100% traceability, and rapid identification and correction of quality issues.


Request a Free sample to learn more about this report.


Contract Manufacturing Organizations (CMO) Market Growth Factors


Rising Outsourcing of Biologics and Biosimilars Manufacturing to Boost Market Growth


Over the past few years, the global burden of chronic diseases, including various cancers, diabetes, and neurological disorders, has been rising significantly, increasing the demand for biologics and biosimilars. Such a scenario is encouraging CMOs to enter the market with their specialized drug manufacturing services.



  • For instance, according to the data published by the American Cancer Society (ACS) in January 2023, 1,958,310 new cancer cases were projected to be diagnosed in the U.S. in 2023.


Biologics are complex molecules that require specialized manufacturing skills and facilities, prompting a number of pharmaceutical companies to partner with contract manufacturing organizations (CMOs) for their production.



  • For instance, in April 2024, AGC Biologics collaborated with Var2 Pharmaceuticals ApS to produce cancer-specific therapeutic antibody fragments, covering various aspects - from method implementation to regulatory support.


Moreover, biosimilars, which require a less expensive manufacturing process than biologics, offer comparable safety and efficacy for chronic diseases. This has led to an increased outsourcing of biosimilars by pharmaceutical companies, thereby driving the expansion of CMOs.



  • In November 2023, SwiftPharma BV and PlantForm entered a contract manufacturing agreement to produce antibodies and proteins for PlantForm's pipeline, including a biosimilar of pembrolizumab.


These strategic partnerships and advancements in manufacturing capabilities are expected to significantly drive the demand for biologics and biosimilars in the coming years.


Increased Investment in Expanding Drug Manufacturing Capabilities of CMOs to Drive Market Growth


Increasing demand for pharmaceutical products due to the rise of chronic diseases is prompting CMOs to expand their drug production capacity. As pharmaceutical companies concentrate on core research and development activities, they are increasingly outsourcing the manufacturing of their drugs to CMOs that offer specialized expertise and advanced technologies.



  • For instance, in March 2024, Tonix Pharmaceuticals selected two CMOs for the launch of Tonmya (cyclobenzaprine), a treatment for fibromyalgia.

  • Similarly, Ferring and SK Pharmteco Inc. entered a commercial agreement in April 2024 to enhance the manufacturing capacity for Ferring's gene therapy, Adstiladrin. These partnerships are crucial for ensuring a stable supply of medications, which is expected to boost the demand for contract manufacturing services, driving the market growth in the coming years.


Furthermore, to meet this growing demand, CMOs are investing significantly in their facilities and upgrading their capabilities by constructing new manufacturing sites, implementing continuous manufacturing processes, and adopting advanced analytical techniques. These measures will help them improve their efficiency and quality of service.



  • For instance, Catalent, Inc. announced a USD 350 million investment in April 2022 to expand its biologics manufacturing capabilities in Indiana, U.S.


Such production expansions are expected to enable CMOs to provide integrated solutions that streamline the drug development process, ultimately driving the market growth in the coming years.


RESTRAINING FACTORS


High Costs Associated With Establishing Production Facilities May Hinder Market Expansion


Despite the growing demand for pharmaceutical outsourcing, several factors are limiting the entry of new Contract Manufacturing Organizations (CMOs) in the global market, which may restrict the market growth.


Establishing a new manufacturing facility is a complex, costly, and time-consuming process as it includes designing of manufacturing processes, scaling up of production, building the supply chain, complying with regulations, and constructing the physical facility. Even expanding an existing facility or transferring a single product to a new site can take several years.



  • For instance, in April 2023, the Pharmaceutical Research and Manufacturers of America (PhRMA) stated that building just one production facility can cost up to USD 2 billion. Furthermore, they also stated that the completion of this facility can take 5-10 years before it is even operational. Such high investments are creating barriers to entry for companies looking to establish their in-house manufacturing capabilities and provide production services to others.


Additionally, pharmaceutical companies may be hesitant to rely on Contract Manufacturing Organizations (CMOs) for critical operations, such as drug manufacturing as they prioritize product quality and security. These high barriers to entry, coupled with the substantial costs of setting up production facilities, are expected to limit market expansion in the coming years.


Contract Manufacturing Organizations (CMO) Market Segmentation Analysis


By Service Analysis


To know how our report can help streamline your business, Speak to Analyst


Outsourcing of API Manufacturing to CMOs Boosted Segment’s Dominance in 2023


Based on service, the market is segmented into API manufacturing, finished product, and packaging. The finished product segment is further sub-segmented into solid dosage forms, injectables, and others.


The API manufacturing segment accounted for the maximum global Contract Manufacturing Organizations (CMO) market share in 2023. This growth can be attributed to the increasing focus of global pharmaceutical companies on outsourcing the production of their API to specialized Contract Manufacturing Organizations (CMO). This initiative can offer several other benefits and provide cost-effective solutions, especially in emerging countries. Moreover, the rising pharmaceutical exports of API worldwide are expected to increase the manufacturing demand, representing several opportunities for CMOs and driving the segment growth.



  • For instance, in April 2024, the API Innovation Center announced its plans to collaborate with Apertus Pharmaceuticals, LLC for the expansion of its manufacturing capacity in Missouri, U.S. Such initiatives by the key players are anticipated to boost the segment’s growth during the forecast period.


The finished product segment held the second-largest market share in 2023. The segment’s growth can be attributed to the rising preference of pharmaceutical companies for getting their finished products manufactured from Contract Manufacturing Organizations (CMO). This will help them increase their product availability across the globe and focus on other research activities for their therapeutics. Moreover, the high burden of diseases and lower pharmaceutical production capacity in emerging countries have created a dependency on the export of pharmaceuticals, representing lucrative opportunities for the CMOs to expand their manufacturing facilities for finished products in such countries. These factors are projected to boost the segment’s growth during the forecast period.


The packaging segment accounted for a moderate share of the global market in 2023. This growth is attributable to the increasing focus of CMOs on offering significant packaging services to biopharmaceutical companies to ensure the efficient and timely reach of their products in the market.


REGIONAL INSIGHTS


Based on geography, the market has been studied across North America, Europe, Asia Pacific, and the rest of the world.


North America Contract Manufacturing Organizations (CMO) Market Size, 2023 (USD Billion)

To get more information on the regional analysis of this market, Request a Free sample


North America dominated the market with a revenue of USD 47.02 billion in 2023. The growth is attributable to the rising demand for effective and affordable drug production solutions, driven by the need for safer and more effective drugs, especially advanced therapies and biologics. This is propelling the outsourcing trend of such drugs to the Contract Manufacturing Organizations (CMO), which is expected to boost the regional market growth.


The Contract Manufacturing Organizations (CMO) market in Europe accounted for a moderate share in 2023. This growth can be attributed to the presence of key players, thereby contributing to a comparatively higher penetration of contract manufacturing services in the region. Moreover, the expansion of API production facilities caused by a major API shortage in countries, such as the Czech Republic, Poland, and Hungary is also projected to boost the regional market growth during the forecast period.



  • For instance, in July 2024, Boehringer Ingelheim International GmbH, a European pharmaceutical company, was offering biopharmaceutical development and manufacturing services with a specific focus on mammalian cell culture and drug products.


Asia Pacific held the second-largest market share in 2023 mainly due to improvement in the healthcare infrastructure of Asian countries over the past decade. In addition, the rise in the number of pharmaceutical companies is expected to represent lucrative opportunities for CMOs to construct new facilities in this regions, thereby propelling market growth.


The rest of the world is expected to record a significant CAGR during the forecast period. The growth of these regions can be attributed to the growing focus of CMOs on expanding their presence in the underserved countries of various region. Moreover, the high burden of diseases and lower pharmaceutical production facilities are offering significant opportunities for CMOs to expand their presence in these regions. This factor is expected to boost the Contract Manufacturing Organizations (CMO) market growth.


KEY INDUSTRY PLAYERS


Lonza, Catalent, Inc., and Thermo Fisher Scientific Inc. Held Substantial Market Shares Owing to Strong Focus on Expansion of Manufacturing Facilities


The market is highly fragmented, with prominent players, such as Lonza, Catalent, Inc., and Thermo Fisher Scientific Inc. accounting for a substantial market share in 2023. The major market share of these companies is attributed to their strong focus on the expansion of manufacturing facilities to provide services to pharmaceutical companies worldwide. Moreover, their increased focus on signing collaborative agreements with other pharmaceutical companies to manufacture their therapeutic products is also expected to enhance their market share.



  • For instance, in May 2023, Catalent, Inc. partnered with Siren Biotechnology to support the development and manufacturing of Siren Biotechnology's AAV immuno-gene therapies.


Other prominent players, such as WuXi Biologics, Samsung Biologics, and other small and medium-sized market players are focusing on various strategies, such as service expansion, geographic expansion, partnerships, and collaborations to enhance their market share in the forthcoming years.


List of Top Contract Manufacturing Organizations (CMO) Companies:



  • Boehringer Ingelheim International GmbH (Germany)

  • Almac Group (Ireland)

  • Recipharm AB (Sweden)

  • Dr. Reddy’s Laboratories Ltd. (India)

  • FAMAR Health Care Services (Greece)

  • Lonza (Switzerland)

  • Vetter Pharma-Fertigung GmbH & Co. KG (Germany)

  • Jubilant Pharmova Limited (India)

  • Catalent, Inc. (U.S.)


KEY INDUSTRY DEVELOPMENTS:



  • April 2024: Lonza collaborated with Acumen Pharmaceuticals, Inc. to manufacture Sabirnetug (ACU193), the first monoclonal antibody for the treatment of Alzheimer’s disease.

  • May 2023: Catalent, Inc. partnered with Siren Biotechnology to support the development and manufacturing of Siren Biotechnology's AAV immuno-gene therapies.

  • June 2023: Vetter Pharma-Fertigung GmbH & Co. KG announced plans to expand its manufacturing capacity in the U.S. to meet the increasing customer demands.

  • February 2023: Lonza completed the expansion of its conjugation facility in Visp, Switzerland. This facility includes two manufacturing suites and supporting infrastructure.

  • January 2023: Lonza celebrated the commencement of its first large-scale commercial drug product manufacturing site in Stein. The company's new facility allowed it to offer a complete range of services for the entire life cycle of a drug, including commercial supply.


REPORT COVERAGE


The report provides a detailed analysis of the competitive landscape. It focuses on crucial aspects, such as market dynamics. Additionally, it covers key industry developments, such as mergers, partnerships, acquisitions, regulatory scenarios, and technological advancements in the market. Moreover, it covers key aspects, including analysis of different segments in various regions, company profiles of key players, and the impact of COVID-19 on the market. The report also comprises qualitative and quantitative insights that contribute to the market growth.


To gain extensive insights into the market, Request for Customization


Report Scope & Segmentation













































ATTRIBUTE



DETAILS



Study Period



2019-2032



Base Year



2023



Estimated Year



2024



Forecast Period



2024-2032



Historical Period



2019-2022



Growth Rate



CAGR of 8% from 2024-2032



Unit



Value (USD Billion)



 Segmentation



By Service



  • API Manufacturing

  • Finished Product


    • Solid Dosage Forms

    • Injectables

    • Others


  • Packaging



By Region



  • North America (By Service and Country)


    • U.S.

    • Canada


  • Europe (By Service and Country/Sub-region)


    • Germany

    • U.K.

    • France

    • Italy

    • Spain

    • Scandinavia

    • Rest of Europe


  • Asia Pacific (By Service and Country/Sub-region)


    • India

    • China

    • Japan

    • Australia

    • Rest of Asia Pacific


  • Rest of the World (By Service)



 



Author

Bhushan Pawar ( Assistant Manager -Healthcare )

Bhushan is a seasoned professional with nearly a decade of experience in consulting and market re...Read More...


Frequently Asked Questions

Fortune Business Insights says that the global market stood at USD 145.32 billion in 2023 and is projected to reach USD 289.68 billion by 2032.

In 2023, the North America market value stood at USD 47.02 billion.

The market is expected to exhibit a CAGR of 8% during the forecast period.

By type, the API manufacturing segment leads as it captured a dominant share in 2023.

The rising outsourcing of biosimilars and biologics manufacturing services, increasing investments, and technological advancements in drugs manufacturing are the key factors driving the market growth.

Lonza, Catalent, Inc., and Thermo Fisher Scientific Inc. are the top players in the market.

North America dominated the market in 2023 by holding the largest share.

Seeking Comprehensive Intelligence on Different Markets?
Get in Touch with Our Experts
Speak to an Expert
  • 2019-2032
  • 2023
  • 2019-2022
  • 107
Multi-report Purchase Plan
    A Customized Plan Will be Created Based on the number of reports you wish to purchase
Client Testimonials

“We are quite happy with the methodology you outlined. We really appreciate the time your team has spent on this project, and the efforts of your team to answer our questions.”

- One of the largest & renowned medical research centers based in the U.S. on a report on the U.S. NIPT Market.

“Thanks a million. The report looks great!”

- Feedback from a consultant on a report on the U.S. Beef Market.

“Thanks for the excellent report and the insights regarding the lactose market.”

- Brazil based company specializing in production of protein ingredients.

“I liked the report; would it be possible to send me the PPT version as I want to use a few slides in an internal presentation that I am preparing.”

- Global Digital Services Agency on a report on the Global Luxury Goods Market.

“This report is really well done and we really appreciate it! Again, I may have questions as we dig in deeper. Thanks again for some really good work.”

- U.S.-based biotechnology company focussing on treatment of chronic pain.

“Kudos to your team. Thank you very much for your support and agility to answer our questions.”

- Europe-based provider of solutions to automate data centre operations.

“We appreciate you and your team taking out time to share the report and data file with us, and we are grateful for the flexibility provided to modify the document as per request. This does help us in our business decision making. We would be pleased to work with you again, and hope to continue our business relationship long into the future.”

- India-based manufacturer of industrial and specialty intermediates with a strong global presence.

“I want to first congratulate you on the great work done on the Medical Platforms project. Thank you so much for all your efforts.”

- One of the largest cosmetics company in the world.

“Thank you very much. I really appreciate the work your team has done. I feel very comfortable recommending your services to some of the other startups that I’m working with, and will likely establish a good long partnership with you.”

- U.S. based startup operating in the cultivated meat market.

“We received the below report on the U.S. market from you. We were very satisfied with the report.”

- Global hearing aids manufacturer.

“I just finished my first pass-through of the report. Great work! Thank you!”

- U.S. based solar racking solutions provider.

“Thanks again for the great work on our last partnership. We are ramping up a new project to understand the imaging and imaging service and distribution market in the U.S.”

- World’s leading advisory firm.

“We feel positive about the results. Based on the presented results, we will do strategic review of this new information and might commission a detailed study on some of the modules included in the report after end of the year. Overall we are very satisfied and please pass on the praise to the team. Thank you for the co-operation!”

- Germany based machine construction company.

“Thank you very much for the very good report. I have another requirement on cutting tools, paper crafts and decorative items.”

- Japanese manufacturing company of stationery products.

“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”

- One of the Leading Food Companies in Germany

“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”

- Intuitive Surgical

“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”

- Major Food Company in Japan

“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”

- Ziering Medical

“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”

- Major Manufacturer of Precision Machine Parts in India

“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”

- Hewlett-Packard

“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”

- Global Management Consulting Firm

“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”

- UK-based Start-up in the Medical Devices Sector

“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”

- One of the Largest Companies in the Defence Industry
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . Privacy.
X